| Similar Articles |
|---|
 |
Chemistry World
March 12, 2007 |
Akzo Nobel Sells Medicines Business to Schering Plough US drug giant Schering-Plough is to buy Dutch chemical company Akzo Nobel's pharmaceuticals and animal health business, Organon BioSciences, for 11 billion euros.   |
Chemistry World
March 29, 2007 |
Sanofi-Aventis and Oxford BioMedica Enter Licensing Agreement UK biotech firm Oxford BioMedica has licensed its leading cancer drug, TroVax, to France's Sanofi-Aventis. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Pharmaceutical Executive
December 1, 2005
Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. |
Pharmaceutical Executive
May 1, 2011
Cacciotti & Clinton |
12th Annual Pharm Exec 50 Pharm Exec's annual run-down of the world's biggest pharma companies. |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
The Motley Fool
August 7, 2007
Brian Orelli |
Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering. |
The Motley Fool
August 28, 2008
Brian Orelli |
Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy. |
The Motley Fool
November 27, 2007
Brian Orelli |
Ploughing Into Acquisition Rewards Schering-Plough reaps its first New Drug Application from its purchase of Organon. Investors, take note. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
BusinessWeek
May 14, 2007
Arlene Weintraub |
Schering-Plough Climbs Out Of Its Sickbed Fred Hassan said getting drugmaker Schering-Plough on its feet might take years. Investors are beginning to see the virtues of patience |
The Motley Fool
June 4, 2009
Brian Orelli |
MegaMergers Going to the Dogs It looks like Merck isn't sure it'll be able to get its acquisition of Schering-Plough past regulators without doing a little trimming. |
BusinessWeek
April 16, 2007
Arlene Weintraub |
Big Pharma's Animal Spirits Sales of medicine for pets and livestock are giving drugmakers a welcome boost. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
March 26, 2009
Brian Orelli |
Big Pharma's R&D Model Is Broken Bigger isn't always better. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
The Motley Fool
February 9, 2009
Robert Steyer |
Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
The Motley Fool
October 23, 2007
Brian Orelli |
Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth. |
The Motley Fool
September 24, 2008
Brian Lawler |
Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva. |
The Motley Fool
October 21, 2008
Brian Orelli |
Schering Buys Great Growth Acquiring Organon Biosciences saves the company from a rough quarter. |
Chemistry World
June 22, 2007
Ned Stafford |
Big Pharma Not Interested in 'Male Pill' German drug giant Bayer has officially stopped research and development of a hormonal male contraceptive, yet another sign that the pharma industry has lost interest in developing the so-called 'male pill.' |
